Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells

Area of Science:

• Immunology
• Cell Biology
• Biotechnology

Background:

• Adoptive cell therapy (ACT) with chimeric antigen receptor (CAR) T cells has shown significant clinical success, particularly in refractory cancers.
• Current CAR T-cell therapy faces limitations including lymphopenia-induced T-cell deficiency, T-cell exhaustion from ex vivo expansion, manufacturing variability, and high costs.

Purpose of the Study:

• To review the fundamental aspects of T-cell biology and ACT applications.
• To explore the potential of human induced pluripotent stem cells (iPSCs) as a source for generating universal, off-the-shelf CAR T cells.
• To discuss advancements in T-cell differentiation and genome engineering for next-generation immunotherapies.

Main Methods:

• Review of existing literature on T-cell biology, ACT, iPSC differentiation, and genome engineering techniques.
• Analysis of strategies for generating CAR T cells from iPSCs.
• Discussion of challenges and future directions in developing off-the-shelf CAR T-cell products.

Main Results:

• iPSCs provide a renewable and genetically engineerable source for immune cell generation.
• Various differentiation strategies are being developed to produce T cells from iPSCs.
• Genome engineering advances are enabling the creation of enhanced, off-the-shelf CAR T cells with improved anti-tumor functions.

Conclusions:

• Universal, off-the-shelf CAR T cells derived from iPSCs represent a promising, cost-effective alternative to autologous ACT.
• Further research and development are needed to overcome challenges and realize the full potential of iPSC-derived CAR T cells for cancer immunotherapy.